{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:39:41Z","timestamp":1782369581776,"version":"3.54.5"},"reference-count":44,"publisher":"Wiley","issue":"11-12","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017 SGR 81"],"award-info":[{"award-number":["2017 SGR 81"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001962","name":"World Anti-Doping Agency","doi-asserted-by":"publisher","award":["16C11RV"],"award-info":[{"award-number":["16C11RV"]}],"id":[{"id":"10.13039\/501100001962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Triamcinolone hexacetonide (THA) is a synthetic glucocorticoid (GC) used by intra\u2010articular (IA) administration. GCs are prohibited in sports competitions by systemic routes, and they are allowed by other routes considered of local action (IA administration, among others). The aim of the present work was to study the metabolic profile of THA in urine and plasma following IA administration. Eight patients (4 males and 4 females) with knee osteoarthritis received an IA dose of THA (40 mg) in the knee joint. Spot urine and plasma samples were collected before injection and at different time periods up to day 23 and 10 post\u2010administration, respectively. The samples were analysed by liquid chromatography\u2010tandem mass spectrometry. Neither THA nor specific THA metabolites were detected in urine. Triamcinolone acetonide (TA) and 6\u03b2\u2010hydroxy\u2010triamcinolone acetonide were the main urinary metabolites. Maximum concentrations wereobtained between 24 and 48 h after administration. Using the reporting level of 30 ng\/mL to distinguish allowed from forbidden administrations of GCs, a large number of false adverse analytical findings would be reported up to day 4. On the other hand, TA was detected in all plasma samples collected up to day 10 after administration. THA was also detected in plasma but at lower concentrations. The detection of plasma THA would be an unequivocal proof to demonstrate IA use of THA. A reversible decrease was observed in plasma concentrations of cortisol in some of the patients, indicating a systemic effect of the drug.<\/jats:p>","DOI":"10.1002\/dta.2614","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:44:10Z","timestamp":1557794650000},"page":"1589-1600","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra\u2010articular administration"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0729-4470","authenticated-orcid":false,"given":"Sergi","family":"Coll","sequence":"first","affiliation":[{"name":"IMIM (Hospital del Mar Medical Research Institute) Catalonian Antidoping Laboratory  Barcelona Spain"},{"name":"Department of Experimental and Health Sciences Universitat Pompeu Fabra  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Matabosch","sequence":"additional","affiliation":[{"name":"IMIM (Hospital del Mar Medical Research Institute) Catalonian Antidoping Laboratory  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jone","family":"Llorente\u2010Onaindia","sequence":"additional","affiliation":[{"name":"IMIM (Hospital del Mar Medical Research Institute) Cell Research on Inflammation and Cartilage Group  Barcelona Spain"},{"name":"IMIM (Hospital del Mar Medical Research Institute) Rheumatology Department  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel\u00b7li","family":"Carb\u00f3","sequence":"additional","affiliation":[{"name":"Department of Experimental and Health Sciences Universitat Pompeu Fabra  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"P\u00e9rez\u2010Ma\u00f1\u00e1","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol (IGTP) Department of Clinical Pharmacology  Badalona Spain"},{"name":"Department of Pharmacology, Therapeutics and Toxicology Autonomous University of Barcelona  Cerdanyola del Vall\u00e8s Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Monfort","sequence":"additional","affiliation":[{"name":"IMIM (Hospital del Mar Medical Research Institute) Catalonian Antidoping Laboratory  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Monfort","sequence":"additional","affiliation":[{"name":"IMIM (Hospital del Mar Medical Research Institute) Cell Research on Inflammation and Cartilage Group  Barcelona Spain"},{"name":"IMIM (Hospital del Mar Medical Research Institute) Rheumatology Department  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1413-8890","authenticated-orcid":false,"given":"Rosa","family":"Ventura","sequence":"additional","affiliation":[{"name":"IMIM (Hospital del Mar Medical Research Institute) Catalonian Antidoping Laboratory  Barcelona Spain"},{"name":"Department of Experimental and Health Sciences Universitat Pompeu Fabra  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-014-0205-0"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2007.06.022"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/JSM.0b013e318163f220"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00421-006-0332-4"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjsm.2006.027599"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2016-096664"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3810\/psm.2010.10.1817"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-5-1-1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)06290-X"},{"key":"e_1_2_8_11_1","unstructured":"The World Anti\u2010Doping Code.The 2019 Prohibited List. International Standard. [World Anti\u2010Doping Agency Website]. Available at:https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/wada_2019_english_prohibited_list.pdf(Accessed January 2019)."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2006.05.016"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.1568"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-011-4744-6"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.6129"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-012-6037-0"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2013.05.019"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182787b20"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.6965"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2014.09.018"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2014.07.024"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1770"},{"key":"e_1_2_8_23_1","first-page":"411","volume-title":"Recent advances in doping analysis (13)","author":"Simoes SMS","year":"2005"},{"key":"e_1_2_8_24_1","unstructured":"MataboschX MonfortN PozoOJet al.Urinary profile of betamethasone metabolites after different administration routes. Presented at: 32nd Cologne Workshop on Dope Analysis. Cologne Germany 30th March\u20134thApril 2014."},{"key":"e_1_2_8_25_1","unstructured":"VenturaR MataboschX MonfortN PozoOJ SeguraJ.Urinary profiles of corticosteroids after intra\u2010articular and related administrations. Presented at 33rd Cologne Workshop on Dope Analysis. Cologne Germany 1st\u20106thMarch 2015."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.15.253"},{"key":"e_1_2_8_27_1","unstructured":"CollS MataboschX MonfortN et al.Elimination profile of betamethasone and metabolites in urine after different administration routes. Presented at 22nd International Mass Spectrometry Conference. Florence Italy 26th\u201331stAugust 2018."},{"key":"e_1_2_8_28_1","unstructured":"CollS MataboschX Llorente\u2010OnaindiaJ et al.Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra\u2010articular administration. Presented at 37th Cologne Workshop on Dope Analysis. Cologne Germany 17th\u201321thFebruary 2019."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1070385"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.45"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041525"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1135-x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3928\/01477447-20121120-20"},{"key":"e_1_2_8_34_1","first-page":"89","article-title":"Clinical utility of ultrasound guidance for intra\u2010articular knee injections","volume":"7","author":"Berkoff DJ","year":"2012","journal-title":"Clin Interv Aging"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.0940536"},{"key":"e_1_2_8_36_1","unstructured":"WADA ISTI \u2013 Blood Sample Collection Guidelines [World Anti\u2010Doping Agency Website]. Available at:https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/resources\/files\/guidelines_blood_sample_collection_v5_sept_2016.pdf(Accessed September 2018)."},{"key":"e_1_2_8_37_1","unstructured":"WADA Technical Document \u2010 TD2018DL [World Anti\u2010Doping Agency Website]. Available at:https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/resources\/files\/td2018dl_v1_en.pdf(Accessed September 2018)."},{"key":"e_1_2_8_38_1","first-page":"379","article-title":"Evaluation of urinary lead determinations","volume":"20","author":"Levine L","year":"1996","journal-title":"J Ind Hyg Toxicol"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1790070309"},{"issue":"10","key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jpba.2018.02.052","article-title":"Simultaneous determination of triamcinolone hexacetonide and triamcinolone acetonide in rabbit plasma using a highly sensitive and selective UPLC\u2010MS\/MS method","volume":"153","author":"Sun W","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2015.10.013"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)90001-5"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.76.6.1464"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000370047"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2014.09.029"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.2614","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.2614","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.2614","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.2614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:36:36Z","timestamp":1760348196000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.2614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":44,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1002\/dta.2614"],"URL":"https:\/\/doi.org\/10.1002\/dta.2614","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"2019-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}